stock market online

Ripple prices surged more than 80% Photographer: Chris Ratcliffe/Bloomberg News

Ripple prices have surged in the last few days, building upon their recent gains to rally more than 90% over the last 24 hours.

The price of XRP tokens has climbed to as much as $0.8661, according to CoinMarketCap.

By reaching this level, the digital currency had risen roughly 91.9% in the space of 24 hours and upwards of 300% from the weekly low of $0.2222 it reached on December 8, additional CoinMarketCap figures show.

Many of the major digital currencies – including Litecoin, Ether and Bitcoin – have generated compelling gains this year as the digital currency market surged higher.

stock market online: Guaranty Bancorp(GBNK)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of PATRIOT FINANCIAL PARTNERS GP, LP’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=PATRIOT+FINANCIAL+PARTNERS+GP%2C+LP

    These are the top 5 holdings of PATRIOT FINANCIAL PARTNERS GP, LPBanc of California Inc (BANC) – 2,850,564 shares, 27.82% of the total portfolio. Guaranty Bancorp (GBNK) – 1,891,767 shares, 23.36% of the total portfolio. Shares reduced by 19.22%Meta Financial Group Inc (CASH) – 347,069 shares, 14.02% of the total portfolio. Sterling Bancorp (STL) – 1,048,980 shares, 11.07% of the total portfolio. Shares reduced by 16.01%MBT Financial Corp (MBTF) – 2,060,302 sha

stock market online: Shire plc(SHPG)

Advisors’ Opinion:

  • [By Ben Levisohn]

    We highlight the key takeaways below, which have read-throughs for brand drug companies we cover such asAllergan (AGN), Shire (SHPG), Valeant Pharmaceuticals International, Mallinckrodt,Endo International and Jazz Pharmaceuticals (JAZZ), among others.

  • [By Ben Levisohn]

    Specialty pharmaceuticals Shire (SHPG) and Mallinckrodt (MNK) soared today following their better-than-expected earnings, while Morgan Stanley worried about Valeant Pharmaceutical International’s (VRX) ability to sell its unwanted assets.

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

    From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth.  From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.

    Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for infl

  • [By Todd Campbell]

    The partnered portfolio includes Movantik and Adynovate, which are licensed to AstraZeneca (NYSE:AZN) and Shire (NASDAQ:SHPG), respectively.

    Movantik won Food and Drug Administration approval in September 2014 for use in relievingopioid constipation, and Nektar Therapeutics reports that annual prescriptions jumped 270% year over year in 2016. Currently, Movantik is selling at an annualized clip of about $160 million, and according to the licensing agreement, Nektar Therapeutics receives a 20% plus royalty on U.S. sales, plus potential sales milestone payments.

stock market online: Nustar Energy L.P.(NS)

Advisors’ Opinion:

  • [By Roberto Pedone]

    One technology player that insiders are active in here is Jive Software (NS), which provides a social business software platform to businesses, government agencies, and other enterprises. Insiders are buying this stock into massive weakness, since shares are down sharply by 43% so far in 2014.

     

    Jive Software has a market cap of $446 million and an enterprise value of $365 million. This stock trades at a fair valuation, with a price-to-sales of 2.68 and a price-to-book of 5.67. Its estimated growth rate for this year is 45.5%, and for next year it’s pegged at 30%. This is a cash-rich company, since the total cash position on its balance sheet is $98.18 million and its total debt is $6.60 million.

     

    A director just bought 260,819 shares, or about $1.71 million worth of stock, at $6.53 to $6.60 per share.

     

    From a technical perspective, JIVE is currently trending just above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock recently pulled back off its short-term high of $7.14 a share with heavy downside volume flows. That drop has now pushed the stock to right above its 50-day moving average at $6.10 a share.

    If you’re bullish on JIVE, then I would look for long-biased trades as long as this stock is trending above its 50-day at $6.10 a share and then once it breaks out above some key near-term overhead resistance levels at $7.14 a share to its 200-day moving average of $7.43 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 557,678 shares. If that breakout triggers soon, then JIVE will set up to re-test or possibly take out its next major overhead resistance levels $8.50 to $9 a share, or even $9.50 to $10 a share.

    Must Read: 10 Stocks George Soros Is Buying

stock market online: Safeway Inc.(SWY)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of SUPERVALU underperforming the underperformance ofmid caps Whole Foods Market, Inc (NASDAQ: WFM) and Safeway Inc (NYSE: SWY). while large capKroger Co (NYSE: KR)had outperformed up until the last two years when performance has been more mixed:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap SUPERVALU now underperforming large cap Kroger Co (NYSE: KR) while shares of large cap Whole Foods Market, Inc (NASDAQ: WFM) and mid cap Safeway Inc (NYSE: SWY) appear to be back to where they started at:

Leave a Reply

Your email address will not be published. Required fields are marked *